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Bladder cancer ranks 9th in world cancer incidence and has a high complex nature. 
The most prevalent form of bladder cancer is transitional cell carcinoma (TCC). The 
non-invasive diagnosis of bladder cancer is principally based on the urinary cytology. 
This test has a high specificity but a low sensitivity and an intrinsically subjectivity that 
depends on the pathologist expertise.
Today’s efforts to diagnose early stages of bladder cancer and to predict the 
progression of the disease are based on the discovery of urinary biomarkers. Proteomic 
technologies are providing the tools needed to discover and identify disease-associated 
biomarkers. In this context, the objective of the present work is to use proteomic 
approaches for the identification of novel molecular markers in urine samples.
Urine samples from 10 bladder cancer patients and 10 control subjects were used 
to perform a differential expression analysis. We have designed a simple protocol to 
separate the cellular and soluble components from urine and analyze them separately. 
Protein extracts from urine cells were obtained and analyzed using 2D-DIGE technology. 
Peptide profiles from the soluble component were determined by MALDI TOF mass 
spectrometry.
Several differential protein spots were detected (p<0.05 after FDR correction) by 
2D-DIGE experiments from which only 5 different proteins were identified. One of these 
proteins showed over a ten-fold increase in tumor samples and it being evaluated as a 
biomarker by immunohistochemistry. Peptide profiles are also capable to differentiate 
between the two groups of samples.
